Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899680 | 0.85 | LPL (0.51) | LPLLIPGRAB9AKDM4EPOLB | |
| SCHEMBL20505306 | 0.84 | LIPG (0.50) | LPLLIPG | |
| SCHEMBL22408223 | 0.81 | LPL (0.50) | LPLLIPGRAB9AKDM4EPOLB | |
| SCHEMBL20504966 | 0.77 | LPL (0.46) | LPLLIPGGAARAB9AKDM4E | |
| SCHEMBL12492286 | 0.76 | ABL1 (0.61) | GAARAB9AKDM4EHTTALDH1A1 | |
| SCHEMBL23092011 | 0.76 | LIPG (0.51) | LPLLIPG | |
| SCHEMBL25716439 | 0.75 | CA1 (0.43) | LPLLIPG | |
| SCHEMBL14746344 | 0.75 | NPC1 (0.65) | LPLLIPGGAARAB9APOLB | |
| SCHEMBL12492267 | 0.75 | ALDH1A1 (0.63) | LPLLIPGGAARAB9AALDH1A1 | |
| SCHEMBL24608995 | 0.74 | LIPG (0.83) | LPLLIPGESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340529-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-8802864-B2 | Triazolones as fatty acid synthase inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2538787-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GlaxoSmithKline LLC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2012-12-13 | — | — | US | disclosed |
| WO-2011103546-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | LPL 3289/4885LIPG 2940/4885GAA 464/4885 |
| US-20140100213-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | LPL 270/4885LIPG 251/4885GAA 1293/4885 |
| US-20120316151-A1 | TRIAZOLONES AS FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | LPL 340/4885LIPG 247/4885GAA 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.